European chemicals giant BASF says that its newly developed Accelon absorption accelerating technology represents a “breakthrough” in the bioavailability of omega-3 supplements.
The Ludwigshafen, Germany headquartered company presented results of clinical trials showing “significantly increased absorption” with its Accelon process at the GOED Exchange 2018, which took place in Seattle, earlier this month.
BASF says the process delivers “a minimum of four times better absorption” of omega-3 in comparison to other market-leading high concentrate omega-3 products. This, it says, results in a higher delivery of EPA and DHA to cells throughout the body.
“… poorly absorbed products, sometimes compounded by low potency, are likely to have limited benefits … Consumers taking their supplements in good faith risk not enjoying the full range of benefits they are hoping and paying for”
“The bioavailability topic is particularly important because poorly absorbed products, sometimes compounded by low potency, are likely to have limited benefits,” says Øyvind Ihle, head of global omega-3 nutrition at BASF. “Consumers taking their supplements in good faith risk not enjoying the full range of benefits they are hoping and paying for.”